Canaccord raised the firm’s price target on DexCom to $150 from $135 and keeps a Buy rating on the shares. The firm noted they delivered impressive results, beating on the top and bottom lines with another record Q of new patient adds. Revenue guidance was lifted given the strong Q2/1H performance, including robust onboarding of basal-only T2 patients.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See the top stocks recommended by analysts >>
Read More on DXCM: